{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.\n\ncetuximab: given IV","id":"OG000","title":"Arm I (Treatment)"},{"description":"Patients receive regular follow-up care","id":"OG001","title":"Arm II (Control)"}],"populationDescription":"Data was not collected for this outcome","reportingStatus":"POSTED","timeFrame":"Baseline (pre-treatment)","title":"Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies","type":"SECONDARY"}